Samsung Biologics reports fourth quarter and fiscal year 2024 financial results

Recorded Q4'24 consolidated revenue of KRW 1.26 trillion Recorded FY'24 consolidated revenue of KRW 4.55 trillion Poised for further growth with expanded capacity and new service offerings INCHEON, South Korea, Jan. 22, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global...